EXCELSIOR, MN – June 2, 2023 – INNOVATION PARTNERS LLC today announced the appointment of yet another key strategic position in further support of the organization’s strategic growth and expanded service capabilities across Medical Affairs and Education.

Innovation Partners is pleased to announce the formal addition of Dr. Roz Blumenthal to the Innovation Partners Leadership team as of May 8, 2023. Dr. Blumenthal has served the Innovation Partners team in a strategic consultant role and has led the strategy for numerous medical affairs projects for more than three years. In response to the growing demands of clients and expanded expertise across Medical Affairs, Dr. Blumenthal has joined the team in an official capacity, as Executive Director, Medical Affairs. A Ph.D. scientist with an advanced degree from the City University of NY and Mount Sinai Medical School, Dr. Blumenthal boasts more than 30 years of experience as a trained researcher, educator, medical writer, and medical strategist. Her depth of prior experience includes 13 years as an NIH-funded research director for the Garden State Cancer Center, Adjunct Faculty Member at Rutgers University and Montclair University, and grant reviewer for NIH, DOD, Susan G. Komen, and California Breast Cancer Research Program study sections. She has authored more than 80 peer-reviewed articles. Further, Dr. Blumenthal has supported various small molecule and biological agents within the oncology hematology space including through promotional medical communications, core content development, medical strategy, and sales training for more than 15 years.

“After serving as a medical strategy consultant to Innovation Partners for several years seeing the quality of the relationships they have with their clients and the value they bring to each I am excited to join them in this new role, to expand our A-level team of medical experts, and provide service to our clients that is second to none as we further expand our Medical Affairs offerings, “ commented Dr. Blumenthal.

The appointment of Dr. Blumenthal to the Innovation Partners Leadership team follows the appointment of Grace DiBonaventura Beyer, Executive Director, Market Research to the leadership team in April of 2022. Since joining the team, Grace has leveraged her more than 30 years of pharmaceutical and healthcare research experience and extensive knowledge of qualitative, quantitative, and multivariate research methodologies to lead the expansion of the organization’s Market Research service offerings.

Responding to the ever-changing landscape of oncology, hematology, and rare disease, Innovation Partners continues to expand its service offerings to meet the complex and critical needs of the clients they serve, in order to make lives better. This includes deepening their internal capabilities to reflect expanded services in Medical Affairs and Market Research, which continue to serve clients from pre-clinical development through post-launch.

“Roz is a trusted and invaluable colleague and I am thrilled to be welcoming her to the Innovation Partners leadership team. Roz has the proven strategic expertise, unwavering work ethic and extensive experience to continue to serve our clients and expand our Medical Affairs offerings,” said Holly AdamsChief Operating Officer.

For more information on Innovation Partners’ service offerings and a listing of available positions please visit the Innovation Partners Website https://innovationpartners.org.


Innovation Partners, LLC (IP) is an oncology, hematology, and rare disease-focused biomedical consulting company partnering with U.S. and global manufacturers seeking to promote access for their innovations, across the product development continuum, for patients, providers, and payers. Innovations Partners believes there are three keys to success – Inquiry, Illumination, and Information – which lead to healthcare access, to ultimately Make Lives Better. IP serves biopharmaceutical, medical device, medical technology, and molecular diagnostic manufacturers who are seeking to bring their healthcare innovations to a successful market launch and commercialization. IP sets itself apart from other consulting agencies by leveraging its network of influential and wide-reaching relationships, decades of industry experience, and deep expertise to navigate the intricacies of the oncology, hematology, and rare disease markets.  They aim to simplify the complex, turning their analysis into actionable insights across their core service areas of medical affairs and education, market and payer access, and quantitative and qualitative market research.  Since 2011, IP has partnered with more than 50 clients to support more than 70 brands through development and launch strategies.  https://innovationpartners.org/

Kimberly Drager
Senior Director, Business Development